{"id":"W2954341438","doi":"10.1007/s40259-019-00361-6","title":"Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Ankylosing spondylitis; Tolerability; Interleukin 17; Immunology; Disease; Interleukin 23; Interleukin 22; Clinical trial; Psoriasis Area and Severity Index; Spondylitis; Interleukin; Dermatology; Internal medicine; Cytokine; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005571783,0.0008218936,0.001226648,0.0012931,0.0001900582,0.0008821163,0.0007745484,0.00107173,0.002549934],"category_scores_gemma":[0.000522015,0.0002159008,0.0004246067,0.000968099,0.000372294,0.0008932903,0.0005427734,0.002630688,0.001869999],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005681016,"about_ca_system_score_gemma":0.0008606476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001011616,"about_ca_topic_score_gemma":0.00243699,"domain_scores_codex":[0.9998436,0.00002356292,0.00001978532,0.00002472785,0.00006389619,0.00002443732],"domain_scores_gemma":[0.9998165,0.0000700831,0.00003418067,0.000004684746,0.0000465841,0.00002797594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001799921,0.00008026869,0.00007837652,0.005475052,0.00007696605,0.0001374543,0.00002428454,0.0002697622,0.001860116,0.002655552,0.04095797,0.9482042],"study_design_scores_gemma":[0.0001100904,0.0001768151,0.0004222278,0.001411411,0.0001115798,0.0009207886,0.00001957462,0.0001116358,0.0006845193,0.001075826,0.9949399,0.00001567425],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001494934,0.9980856,0.000166272,0.0003253241,0.000434572,0.000006122282,0.00002552469,0.00001043665,0.0007967675],"genre_scores_gemma":[0.001250061,0.9958737,0.0002766041,0.0006359604,0.0003117656,0.000009449,0.00006275728,0.000002707377,0.001576881],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002549934,"threshold_uncertainty_score":0.008530438,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04080093537706545,"score_gpt":0.2807410066708714,"score_spread":0.239940071293806,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}